Takeda Pharmaceutical (NYSE:TAK) Downgraded by Wall Street Zen to Hold

Wall Street Zen downgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a buy rating to a hold rating in a report released on Monday.

Other equities research analysts also recently issued reports about the company. Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Finally, Sanford C. Bernstein upgraded shares of Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research report on Wednesday, April 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

TAK opened at $17.04 on Monday. The company has a quick ratio of 0.60, a current ratio of 1.09 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average price is $16.09 and its two-hundred day moving average price is $16.87. The firm has a market capitalization of $54.22 billion, a P/E ratio of 43.77 and a beta of -0.07. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. The company had revenue of $6.90 billion during the quarter. Takeda Pharmaceutical had a return on equity of 11.20% and a net margin of 4.31%. On average, equities analysts forecast that Takeda Pharmaceutical will post 0.94 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Several large investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in Takeda Pharmaceutical by 37.7% in the third quarter. JPMorgan Chase & Co. now owns 247,529 shares of the company’s stock valued at $3,624,000 after buying an additional 67,770 shares during the period. Capital Research Global Investors boosted its stake in shares of Takeda Pharmaceutical by 0.8% during the 3rd quarter. Capital Research Global Investors now owns 13,404,129 shares of the company’s stock worth $196,236,000 after acquiring an additional 108,556 shares during the period. XY Capital Ltd acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $2,928,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $998,000. Finally, Sivia Capital Partners LLC bought a new stake in Takeda Pharmaceutical in the 2nd quarter valued at $351,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.